{
    "clinical_study": {
        "@rank": "13253", 
        "arm_group": [
            {
                "arm_group_label": "group 1", 
                "arm_group_type": "Experimental", 
                "description": "received one intravenous administration and one oral medication with interval of 1 week,"
            }, 
            {
                "arm_group_label": "group 2", 
                "arm_group_type": "Experimental", 
                "description": "received one oral administration and one intravenous medication with interval of 1 week"
            }
        ], 
        "brief_summary": {
            "textblock": "This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous\n      Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation\n      (Gemifloxacin 320mg) and to explore possibility of clinical use of the IV formulation."
        }, 
        "brief_title": "Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)", 
        "condition": "Infectious Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy Korean males between 19 and 45 years of age, weighing within 15% deviation of\n             the ideal weight (CRC criteria) and residing in Korea (Appendix 4)\n\n          2. Applicants judged eligible as subject based on health exams (interview, blood\n             pressure, 12-lead ECG, physical exam, blood and urine tests, and other screening\n             tests) conducted not more than three weeks prior to administration (those with two or\n             less clinically significant results)\n\n          3. Applicants who can take part in the whole process of clinical study\n\n          4. Applicants who sufficiently received explanation on the purpose and content of\n             clinical study, characteristics of the investigational products, etc., before\n             participating in the study and gave written consent to participate in the study\n             voluntarily\n\n        Exclusion Criteria:\n\n          1. Applicants who exhibit symptoms suspected to be those of acute diseases prior to the\n             start of the study\n\n          2. Clinically significant kidney disease  or liver disease\n\n          3. Cardiovascular, respiratory, renal, endocrine system, hematology (hemorrhagic\n             diathresis), digestive system (peptic ulcer), central nerve system, psychiatric\n             disorder, or malignant tumors; chronic diseases that can influence the absorption,\n             distribution, metabolism, or excretion of drugs\n\n          4. Applicants who have been on an abnormal diet, which can influence the absorption,\n             distribution, metabolism, or excretion of drugs\n\n          5. Medical history of gastrointestinal resection except appendectomy\n\n          6. Applicants testing positive for hepatitis B antigen, hepatitis C antibody, or HIV\n             antibody;\n\n          7. Clinically significant allergic diseases (excluding mild allergic rhinitis that does\n             not require medication)\n\n          8. Known history of hypersensitivity to drugs\n\n          9. Known history of developing complications such as epilepsy or other convulsive\n             diseases\n\n         10. Excessive consumption of caffeine and alcohol or heavy smoker\n\n         11. History of alcohol or drug abuse\n\n         12. Applicants who cannot take the standard meals provided by ASAN Medical Center(AMC)\n\n         13. Donation of whole or apheresis blood prior to the administration\n\n         14. Participation in other clinical study as subjects prior to the administration\n\n         15. Applicants who have taken prescription drugs prior to the administration or\n             OTC(over-the-counter)  drugs prior to the administration and for which such\n             medications are judged by the principal investigator to have an influence on this\n             study or on the safety of the subject\n\n         16. Applicants who are highly likely to take other medication during the study\n\n         17. Applicants who took medication that induces or inhibits drug-metabolizing enzymes\n             such as barbiturates or consumed excessive amounts of alcohol less than 1 month prior\n             to the administration\n\n         18. Medical history of meningitis, encephalitis, or brain injury\n\n         19. Difficulty in cooperating with researchers in proceeding with the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879007", 
            "org_study_id": "LG-AACL006"
        }, 
        "intervention": {
            "arm_group_label": [
                "group 1", 
                "group 2"
            ], 
            "intervention_name": "Factive\u00ae  Tab / Factive IV", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemifloxacin", 
                "Fluoroquinolones"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan medical center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "MRT", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "CL", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "Vss", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }, 
            {
                "measure": "F", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hr"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}